Literature DB >> 28131114

Optimal Pain Management After Cesarean Delivery.

Caitlin Dooley Sutton1, Brendan Carvalho2.   

Abstract

Cesarean delivery rates are increasing worldwide, and effective postoperative pain management is a key priority of women undergoing cesarean delivery. Inadequate pain management in the acute postoperative period is associated with persistent pain, greater opioid use, delayed functional recovery, and increased postpartum depression. In addition to pain relief, optimal management of patients after cesarean delivery should address the goals of unrestricted maternal mobility, minimal maternal and neonatal side effects, rapid recovery to baseline functionality, and early discharge home. Multimodal analgesia should include neuraxial morphine in conjunction with nonopioid adjuncts, with additional oral or intravenous opioids reserved for severe breakthrough pain.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cesarean delivery; Intrathecal opioids; Multimodal analgesia; Pain management

Mesh:

Substances:

Year:  2016        PMID: 28131114     DOI: 10.1016/j.anclin.2016.09.010

Source DB:  PubMed          Journal:  Anesthesiol Clin        ISSN: 1932-2275


  19 in total

Review 1.  [The new S1 guidelines "Obstetric analgesia and anesthesia"-Presentation and comments].

Authors:  Dorothee H Bremerich; Susanne Greve
Journal:  Anaesthesist       Date:  2021-01-19       Impact factor: 1.041

2.  Transversus abdominis plane block compared with wound infiltration for postoperative analgesia following Cesarean delivery: a systematic review and network meta-analysis.

Authors:  Pervez Sultan; Selina D Patel; Sandra Jadin; Brendan Carvalho; Stephen H Halpern
Journal:  Can J Anaesth       Date:  2020-10-09       Impact factor: 5.063

Review 3.  A Review of the Impact of Obstetric Anesthesia on Maternal and Neonatal Outcomes.

Authors:  Grace Lim; Francesca L Facco; Naveen Nathan; Jonathan H Waters; Cynthia A Wong; Holger K Eltzschig
Journal:  Anesthesiology       Date:  2018-07       Impact factor: 7.892

4.  The Anesthetic Effect and Safety of Dexmedetomidine in Cesarean Section: A Meta-Analysis.

Authors:  Gang Pang; Yuanmao Zhu; Yan Zhou; Shanshan Tong
Journal:  Biomed Res Int       Date:  2022-05-14       Impact factor: 3.246

Review 5.  Perioperative Pain Management and Opioid Stewardship: A Practical Guide.

Authors:  Sara J Hyland; Kara K Brockhaus; William R Vincent; Nicole Z Spence; Michelle M Lucki; Michael J Howkins; Robert K Cleary
Journal:  Healthcare (Basel)       Date:  2021-03-16

6.  Lidocaine patches for postcesarean pain control in obese women: a pilot randomized controlled trial.

Authors:  Kathleen M Antony; Jacquelyn H Adams; Laura Jacques; Scott Hetzel; Richard J Chappell; Sarah E Gnadt; Amye J Tevaarwerk
Journal:  Am J Obstet Gynecol MFM       Date:  2020-11-26

7.  Improved Outcomes Associated With the Use of Intravenous Acetaminophen for Management of Acute Post-Surgical Pain in Cesarean Sections and Hysterectomies.

Authors:  Richard D Urman; Elaine A Boing; An T Pham; Victor Khangulov; Randi Fain; Brian H Nathanson; Xuan Zhang; George J Wan; Belinda Lovelace; Jessica Cirillo
Journal:  J Clin Med Res       Date:  2018-04-13

8.  Transversus abdominis plane block with liposomal bupivacaine for pain control after cesarean delivery: a retrospective chart review.

Authors:  B Wycke Baker; Lea G Villadiego; Y Natasha Lake; Yazan Amin; Audra E Timmins; Laurie S Swaim; David W Ashton
Journal:  J Pain Res       Date:  2018-12-10       Impact factor: 3.133

9.  Comparison of different sufentanil-tramadol combinations for pain relief within the first 24 hours after cesarean section: a retrospective study.

Authors:  Xueqin Cao; Xianwei Zhang
Journal:  J Pain Res       Date:  2018-10-23       Impact factor: 3.133

10.  Bupivacaine Pharmacokinetics and Breast Milk Excretion of Liposomal Bupivacaine Administered After Cesarean Birth.

Authors:  Hiba J Mustafa; Henry L Wong; Mahmoud Al-Kofahi; Malinda Schaefer; Ashwin Karanam; Michael M Todd
Journal:  Obstet Gynecol       Date:  2020-07       Impact factor: 7.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.